Taken together, the overexpression of SET suppressed tamoxifen-induced anti-cancer effects and upregulated ERE-dependent ER signaling transactivation, indicating that SET may be associated with the failure of tamoxifen treatment in ER-positive breast cancer, at least, in part, through modulating the ER signaling pathway. Here, SET is linked to cancer.